Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

1.

Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.

Dykes C, Wu H, Sims M, Holden-Wiltse J, Demeter LM.

J Clin Microbiol. 2010 Nov;48(11):4035-43. doi: 10.1128/JCM.00605-10. Epub 2010 Sep 8.

PMID:
20826651
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Wang J, Bambara RA, Demeter LM, Dykes C.

J Virol. 2010 Sep;84(18):9377-89. doi: 10.1128/JVI.00618-10. Epub 2010 Jun 30.

PMID:
20592075
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.

Wang J, Liang H, Bacheler L, Wu H, Deriziotis K, Demeter LM, Dykes C.

Virology. 2010 Jul 5;402(2):228-37. doi: 10.1016/j.virol.2010.03.018. Epub 2010 Apr 18.

PMID:
20399480
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.

Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.

PMID:
20124001
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1.

Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC.

J Virol. 2009 Aug;83(16):8289-92. doi: 10.1128/JVI.00709-09. Epub 2009 May 27.

PMID:
19474095
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Real-time PCR analysis of HIV-1 replication post-entry events.

Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK.

Methods Mol Biol. 2009;485:55-72. doi: 10.1007/978-1-59745-170-3_5.

PMID:
19020818
[PubMed - indexed for MEDLINE]
7.

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

Takeuchi Y, McClure MO, Pizzato M.

J Virol. 2008 Dec;82(24):12585-8. doi: 10.1128/JVI.01726-08. Epub 2008 Oct 8.

PMID:
18842727
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision.

Radzio J, Sluis-Cremer N.

Mol Pharmacol. 2008 Feb;73(2):601-6. Epub 2007 Nov 16.

PMID:
18024510
[PubMed - indexed for MEDLINE]
Free Article
9.

HIV-1 drug-resistance and drug-dependence.

Baldwin C, Berkhout B.

Retrovirology. 2007 Oct 25;4:78. Review.

PMID:
17961213
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.

Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G.

PLoS Pathog. 2006 Nov;2(11):e119.

PMID:
17096588
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Rationale and uses of a public HIV drug-resistance database.

Shafer RW.

J Infect Dis. 2006 Sep 15;194 Suppl 1:S51-8. Review.

PMID:
16921473
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Dykes C, Wang J, Jin X, Planelles V, An DS, Tallo A, Huang Y, Wu H, Demeter LM.

J Clin Microbiol. 2006 Jun;44(6):1930-43. Erratum in: J Clin Microbiol. 2007 Jun;45(6):2102.

PMID:
16757582
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.

Wapling J, Moore KL, Sonza S, Mak J, Tachedjian G.

J Virol. 2005 Aug;79(16):10247-57.

PMID:
16051818
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Acceptor RNA cleavage profile supports an invasion mechanism for HIV-1 minus strand transfer.

Chen Y, Balakrishnan M, Roques BP, Bambara RA.

J Biol Chem. 2005 Apr 15;280(15):14443-52. Epub 2005 Jan 18.

PMID:
15657044
[PubMed - indexed for MEDLINE]
Free Article
16.

Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.

Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N.

FEBS Lett. 2005 Jan 17;579(2):379-84.

PMID:
15642347
[PubMed - indexed for MEDLINE]
Free Article
17.

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B.

J Virol. 2004 Nov;78(22):12428-37.

PMID:
15507629
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF.

J Virol. 2004 Feb;78(4):1718-29.

PMID:
14747537
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Steps of the acceptor invasion mechanism for HIV-1 minus strand strong stop transfer.

Chen Y, Balakrishnan M, Roques BP, Bambara RA.

J Biol Chem. 2003 Oct 3;278(40):38368-75. Epub 2003 Jul 22.

PMID:
12878597
[PubMed - indexed for MEDLINE]
Free Article
20.

Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.

Menzo S, Monachetti A, Balotta C, Corvasce S, Rusconi S, Paolucci S, Baldanti F, Bagnarelli P, Clementi M.

AIDS. 2003 Mar 28;17(5):663-71.

PMID:
12646788
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk